复方丹参注射液联合拉贝洛尔对重度子痫前期患者血清VEGF、Ang Ⅱ水平及母婴结局的影响

Effects of compound danshen injection combined with labetalol on changes of serum VEGF and Ang Ⅱ levels and maternal and infant outcomes in patients with severe preeclampsia

目的探讨复方丹参注射液联合拉贝洛尔对重度子痫前期患者血清血管内皮生长因子（VEGF）、血管紧张素Ⅱ（AngⅡ）水平变化及母婴结局的影响。方法选取86例重度子痫前期患者，按照治疗方案分组，每组43例。对照组给予拉贝洛尔治疗，观察组给予拉贝洛尔＋复方丹参注射液治疗。对比两组治疗前后血清VEGF、AngⅡ水平及炎性因子[肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）]水平，并统计两组治疗期间不良反应发生率、母婴结局。结果两组血清VEGF、AngⅡ水平及TNF-α、IL-6水平治疗前比较，差异未见统计学意义（P〉0.05），治疗后，观察组血清VEGF高于对照组，AngⅡ及TNF-α、IL-6低于对照组，差异有统计学意义（P〈0.05）；观察组不良反应发生率11.63%（5/43）与对照组9.30%（4/43）比较，差异未见统计学意义（P〉0.05）；观察组早产、产后出血、胎儿窘迫发生率[9.30%（4/43）、9.30%（4/43）、4.56%（4.56）]均低于对照组[3.26%（11/43）、30.23%（13/43）、18.60%（8/43）]，差异有统计学意义（P〈0.05）。结论给予重度子痫前期复方丹参注射液联合拉贝洛尔治疗，可有效改善患者血清VEGF、AngⅡ水平，减轻炎症反应，临床效果显著，且具有一定安全性，有利于改善母婴结局。

Objective To investigate the effects of compound danshen injection combined with labetalol on serum vascular endothelial growth factor （VEGF） and angiotensin Ⅱ （AngⅡ） levels and maternal and child outcomes in patients with severe preeclampsia. MethodsA total of 86 patients with severe pre-eclampsia were selected and divided according to the treatment regimen, with 43 cases in each group. The control group was treated with labetalol and the observation group was treated with labetalol ＋ compound danshen injection. The levels of serum VEGF, AngⅡ and inflammatory factors [tumor necrosis factor-α （TNF-α）, interleukin-6 （IL-6）] were compared between the two groups before and after treatment, and the incidence of adverse reactions and maternal and child outcomes cluring treatment of the two groups wee relorded.ResultsThere was no significant difference in serum VEGF, AngⅡ levels, TNF-α or IL-6 levels between the two groups before treatment （P〉0.05）, but after treatment, the serum VEGF level in the observation group was higher than that in the control group, and the levels of AngⅡ and TNF-α and IL-6 were lower than those in the control group, the differences were significant （P〈0.05）; there was no significant difference in the incidence of adverse reactions between the observation group [11.63% （5/43）] and the control group [9.30% （4/43）] （P〉0.05）; the preterm labor, postpartum hemorrhage and incidence of fetal distress in the observation group [9.30% （4/43）, 9.30% （4/43） and 4.56% （4.56）]were significantly lower than those in the control group [3.26% （11/43）, 30.23% （13/43）, 18.60% （8/43）], the differences were significant （P〈0.05）.ConclusionsCompound danshen injection combined with labetalol for treatment of severe preeclampsia can improve the serum VEGF and AngⅡlevels, reduce the inflammatory response, has significant clinical effect and high safety, and is helpful to improve the maternal and child outcomes.